The DOI matches its Crossref record; the references it cites are not checked yet.
CD137 stimulation enhances the vaccinal effect of anti-tumor antibodies
Open accessAbstract
Some evidence suggests that monoclonal antibodies (mAb) can induce an adaptive immune response against tumor cells ("vaccinal effect"). Recently, we have shown that an anti-CD137 mAb can enhance the "vaccinal effect" of an anti-tumor mAb (cetuximab), thereby transforming a passive, monoclonal, short-term immunotherapy into an active, polyclonal, long-lasting immune response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The combination of cetuximab with anti-CD137 mAb administration was synergistic and resulted in complete tumour resolution and prolonged survival, dependent on NK cells.
“The combination of cetuximab with anti-CD137 mAb administration was synergistic and resulted in complete tumour resolution and prolonged survival, which were dependent on the participation of NK cells [52].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [52]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists haven’t been fetched yet
References 10 · Cited by 15
Research works printed but not linked: 1
- Kohrt HE, 2014, J Clin Invest
Metadata
- Authors
- Houot, R., & Kohrt, H.
- Affiliations
- Inserm (FR)
- Stanford Medicine (US)
- Corresponding author
- Kohrt, Holbrook
- ORCID
- Houot, Roch
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2014-07-03
- Volume
- 3
- Issue
- 7
- Pages
- e941740
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- PMC
- PMC4292240
- OpenAlex
- W2089955339
- Cited by
- 15
- References
- 10
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2021: 1 · 2019: 3 · 2017: 1 · 2016: 3 · 2015: 4
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- OncoImmunology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- 4-1BB, cetuximab, anti-tumor antibodies, antibody-dependent cellular cytotoxicity, cancer immunotherapy, adaptive immune response, monoclonal antibodies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
